Scientific deep-dive
Foundayo vs Wegovy: Head-to-Head Evidence Comparison
Foundayo (orforglipron) is an oral small-molecule GLP-1 tablet; Wegovy (semaglutide) is a weekly injection or daily tablet. ATTAIN-1 ~11.1% weight loss vs STEP-1 ~14.9% and OASIS 4 (tablet) ~13.6%. Trial data, side effects, CV evidence, dosing rules, and a decision framework.
This head-to-head evidence review is part of Weight Loss Rankings’ living editorial database — 1,180+ research articles and 640+ editorially reviewed GLP-1 telehealth providers, sourced only from FDA prescribing information on DailyMed and peer-reviewed PubMed literature.
Foundayo (orforglipron) and Wegovy (semaglutide) are both GLP-1 receptor agonists FDA-approved for chronic weight management, but they are different molecules with different delivery routes, different FDA labels, and different cardiovascular evidence. Wegovy produces modestly more weight loss at maximum dose. Foundayo is the first non-peptide, small-molecule GLP-1 pill approved for obesity, and since late 2025 Wegovy itself also comes as a daily tablet, so “pill vs shot” is no longer the whole comparison. This article walks through the head-to-head evidence with the trial and FDA-label citations behind every claim.
The honest short answer
Wegovy has a modest edge in mean weight loss; Foundayo wins on dosing simplicity. STEP-1 reported about −14.9% mean body weight on Wegovy 2.4 mg weekly at 68 weeks, and OASIS 4 reported −13.6% on the Wegovy 25 mg tablet at 64 weeks; ATTAIN-1 reported approximately −11.1% on Foundayo’s top 17.2 mg dose at 72 weeks. No trial has compared the two drugs directly. Foundayo is the only GLP-1 pill with no food or water timing rules. Wegovy also carries an FDA cardiovascular indication based on SELECT; Foundayo does not.
Compare vetted semaglutide providers
WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. How we make money
No insurance needed · HSA/FSA eligible · vetted by our editors
Collective
The lowest flat medication price if you can absorb an annual membership fee
Starting price: $59/mo (+ required membership)
Get started →Read review Collective →CoreAge Rx
Lowest-price compounded semaglutide and tirzepatide with one flat price at every dose
Starting price: $79/mo (starting price)
Get started →Read review CoreAge Rx →Embody
Low flat-rate compounded GLP-1 pricing at every dose
Starting price: $79/mo (sale price)
Get started →Read review Embody →Gala
Compounded semaglutide or tirzepatide at one all-doses price on a yearly plan, with free shipping
Starting price: $129/mo (starting dose)
Get started →Read review Gala →Found
Medication-included compounded GLP-1 on 28-day cash plans, plus insurance help for brand-name GLP-1s
Starting price: $169/mo (12-month plan rate)
Get started →Read review Found →| Provider | Starting price | |
|---|---|---|
8.3Collective | $59/mo (+ required membership) | Get started → |
8.3CoreAge Rx | $79/mo (starting price) | Get started → |
7.8Embody | $79/mo (sale price) | Get started → |
8.2Gala | $129/mo (starting dose) | Get started → |
8.3Found | $169/mo (12-month plan rate) | Get started → |
Two different molecules at the same receptor
Both drugs target the glucagon-like peptide-1 receptor (GLP-1R) on pancreatic beta cells, vagal afferents, and hypothalamic appetite centers. The receptor target is the same. The molecules that hit it are not.
Wegovy is semaglutide, a 31-amino-acid synthetic peptide analog of the natural GLP-1 hormone, with a C18 fatty-diacid side chain that enables binding to circulating albumin and a once-weekly half-life. Because semaglutide is a peptide, swallowing it is inefficient: the Wegovy tablet pairs it with an absorption enhancer (salcaprozate sodium, SNAC) and must be taken fasting with a small amount of water, while the injection bypasses the gut entirely[8]. Manufactured by Novo Nordisk.
Foundayo is orforglipron, a small-molecule non-peptide allosteric GLP-1 receptor agonist with an oral bioavailability profile that allows once-daily tablet administration. Because it is not a peptide, gastrointestinal digestion does not destroy it, and the FDA prescribing information says to take it once daily with or without food[7]. Manufactured by Eli Lilly.
Both molecules are monoagonists — they bind only the GLP-1 receptor. Neither is a dual-agonist like tirzepatide (Zepbound, Mounjaro), which activates both GLP-1 and GIP receptors. For the wider drug-class comparison see the full GLP-1 medication reference.
FDA indications and dose ladders side-by-side
| Attribute | Foundayo (orforglipron) | Wegovy (semaglutide) |
|---|---|---|
| Active molecule | Orforglipron (small-molecule non-peptide) | Semaglutide (31-aa peptide) |
| Manufacturer | Eli Lilly and Company | Novo Nordisk |
| Delivery route | Oral tablet, once daily | Subcutaneous injection once weekly, or oral tablet once daily |
| FDA approval date | April 1, 2026 (weight management) | June 4, 2021 (injection); tablet approved December 2025 |
| Primary indication | Chronic weight management in adults with obesity, or overweight with at least one weight-related medical problem (trials enrolled BMI ≥ 30, or ≥ 27 with a comorbidity) | Chronic weight management in adults with obesity, or overweight with at least one weight-related comorbidity (trials enrolled BMI ≥ 30, or ≥ 27 with a comorbidity); injection also for ages 12+ with obesity and for noncirrhotic MASH with moderate to advanced fibrosis (accelerated approval) |
| Cardiovascular indication | None (ACHIEVE-4 showed CV safety vs insulin glargine in type 2 diabetes, not CV benefit) | Reduce risk of MACE in adults with established CV disease + obesity/overweight (added 2024 based on SELECT; injection and tablet) |
| Dose ladder | 0.8 / 2.5 / 5.5 mg, then 9 / 14.5 / 17.2 mg as needed, once daily (at least 30 days per step) | Injection: 0.25 / 0.5 / 1 / 1.7 / 2.4 mg weekly (4-week steps), optional 7.2 mg. Tablet: 1.5 / 4 / 9 / 25 mg daily (30-day steps) |
| Labeled maximum dose | 17.2 mg daily | 7.2 mg weekly injection (2.4 mg usual); 25 mg daily tablet |
| Food/water restrictions | None — with or without food | Injection: none. Tablet: empty stomach in the morning, up to 4 oz water, wait 30 minutes |
| Storage | Room temperature, no refrigeration | Injection pens refrigerated 36-46°F (single-dose pens up to 28 days unrefrigerated); tablets at room temperature |
| Boxed warning | Thyroid C-cell tumors (class warning; orforglipron did not cause tumors in rodents) | Thyroid C-cell tumors (rodent data) |
Mean total body weight loss: ATTAIN-1 vs STEP-1
Neither Foundayo nor Wegovy has been tested against the other in a randomized weight-loss trial. The closest comparisons available set the Foundayo pivotal trial (ATTAIN-1) beside the Wegovy injection trial (STEP-1) and the Wegovy tablet trial (OASIS 4), all of which enrolled adults with obesity or overweight without type 2 diabetes.
ATTAIN-1: the Foundayo pivotal weight-loss trial
ATTAIN-1 (Wharton et al., NEJM 2025) randomized 3,127 adults with obesity without type 2 diabetes to orforglipron 6 mg, 12 mg, or 36 mg daily, or placebo, with a lifestyle-intervention background, for 72 weeks. Mean weight change was −11.2% with 36 mg vs −2.1% with placebo[1]. The trial used an investigational formulation; the Foundayo label presents the same three arms as the equivalent 5.5, 9, and 17.2 mg tablets, so the 36 mg arm is the labeled 17.2 mg maximum. The label reports −11.1% at 17.2 mg vs −2.1% on placebo[7].
STEP-1: the Wegovy pivotal weight-loss trial
STEP-1 (Wilding et al., NEJM 2021) randomized 1,961 adults with overweight or obesity without diabetes to semaglutide 2.4 mg weekly or placebo, with a lifestyle-intervention background, for 68 weeks. Mean body-weight reduction was −14.9% on semaglutide 2.4 mg vs −2.4% on placebo (treatment-regimen estimand). About half of semaglutide-treated patients (50.5%) reached at least 15% body-weight reduction[4]. The current Wegovy label also allows a 7.2 mg weekly maximum for patients who tolerate 2.4 mg; in its 72-week label trial, 7.2 mg produced −18.8% vs −15.5% on 2.4 mg and −3.9% on placebo[8].
OASIS 4: the Wegovy tablet trial
OASIS 4 (Wharton et al., NEJM 2025) randomized 307 adults with obesity or overweight without diabetes to once-daily oral semaglutide 25 mg or placebo. Mean body-weight change at 64 weeks was −13.6% vs −2.2%[9]. This trial supported the Wegovy tablet, which the FDA approved in December 2025, making Wegovy available in both pill and injection form.
What direct comparisons exist
The only randomized trial pitting orforglipron against semaglutide is ACHIEVE-3 (Rosenstock et al., Lancet 2026), and it answers a different question. In 1,698 adults with type 2 diabetes on metformin, orforglipron 12 mg and 36 mg lowered HbA1c more than oral semaglutide 7 mg and 14 mg (the Rybelsus diabetes doses, not the Wegovy 25 mg dose) at 52 weeks, but gastrointestinal events and discontinuations for adverse events were more frequent with orforglipron (9-10% vs 4-5%)[10]. A Novo Nordisk-funded indirect comparison of OASIS 4 and ATTAIN-1 estimated about 3.2 percentage points more weight loss with the Wegovy 25 mg tablet than with orforglipron 36 mg, with fewer adverse-event discontinuations[12]. Indirect, sponsor-funded analyses are weaker evidence than a randomized head-to-head trial.
The indirect-comparison caveat
ATTAIN-1 and STEP-1 are not directly comparable because they enrolled different patient populations (different baseline weights, slightly different BMI inclusion thresholds, different ethnic and geographic distributions), used different lifestyle-intervention backgrounds, and reported at different timepoints (72, 68, and 64 weeks). The roughly 2.5-4 percentage-point gap between Foundayo (11.1%) and Wegovy (13.6% tablet, 14.9% injection at 2.4 mg) is the best available approximation but is not a head-to-head trial result. No randomized trial comparing Foundayo with Wegovy for weight loss has been published.
Magnitude comparison
Mean total body weight loss in the pivotal weight-management trials: Foundayo 17.2 mg (ATTAIN-1), the Wegovy 25 mg tablet (OASIS 4), Wegovy 2.4 mg injection (STEP-1), and the STEP-1 placebo arm. Not a head-to-head trial: separate trials with different populations and durations.[1][7][9][4]
- Foundayo 17.2 mg labeled max — % body weight at 72 wk11.1 % TBWLATTAIN-1 — adults with obesity, no T2D; FDA label Section 14
- Wegovy 25 mg tablet — % body weight at 64 wk13.6 % TBWLOASIS 4 — adults with obesity or overweight, no diabetes
- Wegovy 2.4 mg — % body weight at 68 wk14.9 % TBWLSTEP-1 pivotal — adults with obesity, no T2D
- STEP-1 placebo — % body weight at 68 wk2.4 % TBWLWegovy diet + lifestyle baseline
Side-effect profile: shared class effects
Because both drugs act on the same receptor, the side-effect profile overlaps heavily. Both share the GLP-1 receptor agonist class effects: nausea, vomiting, diarrhea, constipation, abdominal pain, decreased appetite, and (rarely) acute pancreatitis. Both labels carry the FDA boxed warning for risk of thyroid C-cell tumors. For Wegovy it rests on rodent carcinogenicity data; for Foundayo it is class-based, because orforglipron is not active in rats or mice and produced no rodent tumors. Both contraindicate use in patients with personal or family history of medullary thyroid carcinoma or MEN 2.
Pooled adverse-reaction rates from each drug’s FDA label (Foundayo: 5.5 mg to 17.2 mg in ATTAIN-1 and ATTAIN-2; Wegovy: 2.4 mg injection in its weight-management trials). Cross-label comparisons are approximate because the trials differed:
- Nausea: 26-35% on Foundayo vs 10% placebo; 44% on Wegovy 2.4 mg vs 16% placebo[7][8]. Most events are mild to moderate and cluster in the dose-escalation period for both drugs.
- Vomiting: 13-24% on Foundayo; 24% on Wegovy 2.4 mg.
- Diarrhea: 21-25% on Foundayo; 30% on Wegovy 2.4 mg.
- Constipation: 20-27% on Foundayo; 24% on Wegovy 2.4 mg.
- Discontinuation for adverse reactions: 6-10% on Foundayo (rising with dose) vs 3% on placebo; 6.8% on Wegovy 2.4 mg vs 3.2% on placebo[7][8].
One distinction is unique to Foundayo: drug-interaction rules. The Foundayo label caps the dose at 9 mg daily (not the 17.2 mg maximum) with a strong CYP3A4 inhibitor such as clarithromycin, says to avoid strong CYP3A4 inhibitors that also block OATP1B (such as ritonavir) and strong CYP3A4 inducers (such as carbamazepine), and limits simvastatin to 20 mg daily[7]. Semaglutide is a peptide cleared by proteolysis, not by CYP enzymes, so Wegovy has no comparable CYP interaction; the Wegovy tablet does raise levothyroxine exposure, so thyroid levels may need monitoring[8]. For the deeper Foundayo-specific side-effect breakdown see the Foundayo side-effect evidence review.
Form factor and practical access
Delivery used to be the clearest difference between Foundayo and Wegovy. Since the Wegovy tablet arrived, both drugs can be taken as a daily pill; Wegovy can also be a weekly injection. The practical differences now come down to dosing rules, storage, and how often you take it. If the oral route is the deciding factor for you, you can browse oral GLP-1 telehealth providers to compare access.
- Pill rules. Foundayo is one tablet daily, with or without food[7]. The Wegovy tablet is one tablet daily on an empty stomach in the morning with up to 4 ounces of plain water, then a 30-minute wait before food, drinks, or other oral medicines[8]. Wegovy injection users inject once weekly on a self-selected day.
- Storage. Wegovy injection pens are refrigerated at 36-46°F, with limited room-temperature allowances. Foundayo tablets and Wegovy tablets are both stored at room temperature, so travel and storage no longer favor only Foundayo.
- Needle anxiety. A non-trivial subset of patients who would benefit from a GLP-1 do not start one because of injection aversion. Either pill removes that barrier.
- Routine fit. Foundayo fits any existing pill routine. The Wegovy tablet needs a fasting morning slot of its own, which can clash with other morning medicines.
For the broader landscape of oral GLP-1 options, including the Wegovy tablet and Rybelsus, and the practical differences between them, see the oral GLP-1 pills comparison.
Cardiovascular outcomes: SELECT vs ACHIEVE-4
Wegovy and Foundayo are at very different stages of the cardiovascular outcomes evidence base.
SELECT: the trial that gave Wegovy a CV indication
SELECT (Lincoff et al., NEJM 2023) randomized 17,604 adults aged 45+ with established cardiovascular disease and overweight or obesity but without diabetes to semaglutide 2.4 mg weekly or placebo, with a mean follow-up of 39.8 months. The primary MACE composite (cardiovascular death, nonfatal MI, nonfatal stroke) occurred in 6.5% of the semaglutide group vs 8.0% of placebo (HR 0.80, 95% CI 0.72-0.90, p<0.001). SELECT supported the 2024 FDA label expansion adding a cardiovascular indication to Wegovy[6], and the current label carries that indication for the Wegovy tablet as well[8]. The Wegovy CV indication has practical coverage consequences: it has opened Medicare Part D coverage for Wegovy when prescribed for CV risk reduction in adults with established CV disease and obesity, routing around the statutory Medicare anti-obesity-drug exclusion.
ACHIEVE-4: a cardiovascular safety trial, not a benefit trial
ACHIEVE-4 (Klein et al., Lancet 2026) randomized 2,749 adults with type 2 diabetes and established cardiovascular or chronic kidney disease to orforglipron (up to the dose equivalent to 17.2 mg) or insulin glargine. Over a median of 2 years, major cardiovascular events occurred in 4.2% vs 5.0% (HR 0.84, 95% CI 0.59-1.20), which met the trial’s non-inferiority goal[11]. That establishes cardiovascular safety, but it was not placebo-controlled, enrolled people with diabetes rather than the SELECT population, and did not show superiority. Foundayo does not carry an FDA-approved cardiovascular indication. Patients whose primary clinical concern is cardiovascular risk reduction in addition to weight loss currently have a stronger on-label case for Wegovy than for Foundayo. The ATTAIN-MAINTAIN trial (Aronne 2026) addressed the maintenance question for Foundayo[3] but is not a CV outcomes trial.
Type 2 diabetes context
Wegovy is not FDA-approved for type 2 diabetes (its sister drug, Ozempic, carries the T2D indication for semaglutide). Foundayo is approved for chronic weight management in the obesity population, with the ATTAIN-2 trial (Horn et al., Lancet 2026) supporting the Foundayo profile in adults with T2D plus obesity (−9.6% at the top dose vs −2.5% on placebo at 72 weeks)[2]. Foundayo is not FDA-approved to treat blood sugar in type 2 diabetes, although ACHIEVE-3 showed larger HbA1c reductions than lower-dose oral semaglutide[10]. Patients with T2D have several paths to consider:
- T2D plus obesity, want a pill: Foundayo has dedicated T2D weight-loss data (ATTAIN-2) and no dosing-time rules. The Wegovy tablet’s pivotal weight trial, OASIS 4, excluded people with diabetes.
- T2D plus obesity plus established CV disease, want maximum on-label coverage: Wegovy is on-label for the CV indication based on SELECT; the related sister drug Ozempic is on-label for the T2D + CV indication based on SUSTAIN-6. The prescriber may pick Wegovy or Ozempic depending on the relative weight of the weight-management vs glycemic-control axis.
- T2D without established CV disease, primary goal weight loss: Both Foundayo and Wegovy are reasonable on weight grounds. Choice often comes down to delivery preference and insurance coverage.
For the deeper semaglutide-vs-semaglutide indication comparison see the Wegovy vs Ozempic evidence review.
Cost framing: what actually drives the price gap
Cash-pay pricing and insurance coverage shift constantly, so this article describes the structural cost levers rather than fixing on dollar amounts that will be stale within months. Three levers matter most:
- Self-pay price by dose. Both manufacturers sell directly to self-pay patients and price by dose, and both brands now include a pill. Do not assume the tablet, or Foundayo, is the cheaper option; compare the current price for the specific dose you would take.
- Medicare. The temporary Medicare GLP-1 Bridge, which began July 1, 2026 and has been extended through the end of 2027, covers GLP-1s for obesity, including Foundayo and both forms of Wegovy, for eligible Part D enrollees at a flat copay[13]. Separately, Wegovy’s SELECT-based CV indication is a route to standard Part D coverage that Foundayo does not have.
- Commercial insurance. Coverage for either drug depends on the specific formulary, the prior-authorization requirements, and whether the plan covers chronic weight management at all.
Self-pay channels exist for both drugs. Check the manufacturer self-pay program (LillyDirect for Foundayo; NovoCare Pharmacy for Wegovy) and your insurance formulary tier for current pricing. Compounded semaglutide is no longer broadly available as a routine cash-pay workaround following the February 2025 FDA resolution of the semaglutide shortage; the regulatory window for routine compounding closed at that point.
Which to choose: a decision framework
Mapping the FDA labels, the trial data, the side-effect profile, and the access reality onto patient profiles produces a decision framework rather than a single answer. The right choice for any individual patient is made with a licensed prescriber who has reviewed the full FDA prescribing information for both drugs and the individual’s history.
- Maximum mean weight loss is the goal, willing to inject: Wegovy injection. STEP-1 reported about −14.9% mean body weight at 2.4 mg, with an optional 7.2 mg dose for more, versus Foundayo’s ~11.1% at its top dose.
- Established CV disease + obesity, no T2D: Wegovy. The SELECT-supported CV indication is exactly this population and opens Medicare Part D coverage under the CV indication.
- Needle aversion is the controlling factor: Either pill. The Wegovy tablet had somewhat larger average weight loss in its trial and carries the CV indication; Foundayo has no fasting or water rules and suits people who cannot reliably take a pill on an empty stomach. Compare orforglipron providers to find a telehealth platform that prescribes it.
- Travel-heavy lifestyle or unreliable cold-chain storage: A pill. Both Foundayo and the Wegovy tablet are stored at room temperature; Foundayo is easier to fit around meals and other morning medicines.
- On strong CYP3A4 inhibitors or inducers (for example clarithromycin, ritonavir, or carbamazepine): Wegovy may be the cleaner choice. The Foundayo label caps the dose at 9 mg daily with strong CYP3A4 inhibitors and says to avoid strong inhibitors that also block OATP1B and strong inducers[7]. Wegovy has no CYP-mediated interaction.
- Currently on Wegovy 2.4 mg and wanting to switch to oral: Either the Wegovy tablet or Foundayo, with the prescriber choosing the starting dose and checking tolerability at each step. On average, expect weight loss on either pill to plateau somewhat lower than on the 2.4 mg injection. ATTAIN-MAINTAIN found that switching from injectable semaglutide to Foundayo kept more of the lost weight off than switching to placebo[3].
- Currently on Foundayo 17.2 mg and wanting more weight loss: A reasonable Wegovy switch with re-titration from 0.25 mg weekly. Expect the higher Wegovy maintenance dose to push GI tolerability harder than Foundayo did.
For the broader three-way comparison that also includes Zepbound (tirzepatide), see the Foundayo vs Wegovy vs Zepbound three-drug head-to-head.
Bottom line
- Different molecules, same receptor. Wegovy is a peptide, given as a weekly injection or a daily tablet; Foundayo is a small-molecule daily tablet. Both target the GLP-1 receptor as monoagonists; neither is a dual-agonist like tirzepatide.
- Wegovy edges Foundayo on mean weight loss. STEP-1 reported about −14.9% on Wegovy 2.4 mg weekly and OASIS 4 −13.6% on the Wegovy tablet; ATTAIN-1 reported approximately −11.1% on Foundayo 17.2 mg daily. These are separate trials, not a head-to-head comparison.
- Foundayo wins on dosing simplicity. It is the only GLP-1 pill with no food or water timing rules; the Wegovy tablet requires fasting dosing.
- Cardiovascular evidence currently favors Wegovy. SELECT supported the 2024 Wegovy CV indication. Foundayo’s ACHIEVE-4 trial showed cardiovascular safety against insulin glargine in type 2 diabetes, not a CV benefit.
- Side-effect profile largely overlaps. Both carry the GLP-1 class GI effects and the FDA boxed warning for thyroid C-cell tumors. Foundayo has a unique strong-CYP3A4- inhibitor dose cap that Wegovy does not.
- Cost depends on dose and coverage. Both brands sell self-pay by dose, both are in the temporary Medicare GLP-1 Bridge, and Wegovy’s CV indication adds a separate Medicare coverage route.
Frequently Asked Questions
Related research
- Foundayo vs Wegovy vs Zepbound: 2026 head-to-head — extends this two-drug comparison to a three-way comparison including tirzepatide.
- What is orforglipron (Foundayo)? — the foundational explainer on the molecule, the maker, the mechanism, and the FDA approval.
- Foundayo FDA approval explainer — the April 1, 2026 FDA approval and the dose-ladder details from the label.
- Wegovy vs Ozempic evidence review — the same-molecule, different-FDA-indication comparison on the semaglutide side.
- Tirzepatide vs semaglutide head-to-head review — SURMOUNT-5 direct head-to-head data for the dual-agonist comparison.
- Full GLP-1 medication list reference — every FDA-approved GLP-1 with brand, manufacturer, indication, and dose ladder.
- Foundayo side-effect evidence review — the deeper ATTAIN-1 adverse-event breakdown and the CYP3A4 dose-cap interaction.
- Foundayo drug profile — full label, dose ladder, side-effect rates, and provider availability.
- Wegovy drug profile — full label, dose ladder, side-effect rates, and provider availability.
Further reading
- Wegovy vs Foundayo matchup
- Top semaglutide weight-loss studies (curated PubMed reading list)
- Top oral-GLP-1 questions on Reddit, answered
- PIONEER 6 trial deep-dive (oral semaglutide cardiovascular outcomes)
References
- 1.Wharton S, Aronne LJ, Stefanski A, et al.; ATTAIN-1 Investigators. Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment (ATTAIN-1). Phase 3 randomized trial of orforglipron 6, 12, and 36 mg daily (investigational formulation) vs placebo in 3,127 adults with obesity without type 2 diabetes; mean weight change at 72 weeks was -11.2% with 36 mg vs -2.1% with placebo. The Foundayo label presents these doses as the equivalent 5.5, 9, and 17.2 mg tablets. N Engl J Med. 2025. PMID: 40960239.
- 2.Horn DB, Aronne LJ, Wharton S, et al.; ATTAIN-2 Investigators. Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2). Phase 3 randomized trial in 1,613 adults with type 2 diabetes plus overweight or obesity; mean weight change at 72 weeks was -9.6% with 36 mg vs -2.5% with placebo. Supports the Foundayo weight-management label in people with type 2 diabetes. Lancet. 2026. PMID: 41275875.
- 3.Aronne LJ, Horn DB, le Roux CW, Chao AM, Ho W, Halpern B, et al. Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trial. Adults who had lost weight on injectable tirzepatide or semaglutide in SURMOUNT-5 were switched to daily orforglipron or placebo; at 52 weeks, orforglipron preserved more of the prior weight loss than placebo in both cohorts. Nat Med. 2026. PMID: 42120723.
- 4.Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, McGowan BM, Rosenstock J, Tran MTD, Wadden TA, Wharton S, Yokote K, Zeuthen N, Kushner RF; STEP 1 Study Group. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). Semaglutide 2.4 mg once weekly produced mean body-weight reduction of -14.9% vs -2.4% placebo at 68 weeks (treatment-regimen estimand). The pivotal trial that supported the FDA approval of Wegovy for chronic weight management. N Engl J Med. 2021. PMID: 33567185.
- 5.Rubino D, Abrahamsson N, Davies M, Hesse D, Greenway FL, Jensen C, Lingvay I, Mosenzon O, Rosenstock J, Rubio MA, Rudofsky G, Tadayon S, Wadden TA, Dicker D; STEP 4 Investigators. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity (STEP 4). Withdrawal-to-placebo arm regained approximately 6.9% body weight while the continued-semaglutide arm lost an additional 7.9% over 48 weeks, confirming the chronic-disease framing for injectable GLP-1 maintenance. JAMA. 2021. PMID: 33755728.
- 6.Lincoff AM, Brown-Frandsen K, Colhoun HM, Deanfield J, Emerson SS, Esbjerg S, Hardt-Lindberg S, Hovingh GK, Kahn SE, Kushner RF, Lingvay I, Oral TK, Michelsen MM, Plutzky J, Tornoe CW, Ryan DH; SELECT Trial Investigators. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). Semaglutide 2.4 mg once weekly produced a 20% relative reduction in major adverse cardiovascular events (HR 0.80, 95% CI 0.72-0.90, p<0.001) in adults with established CV disease and overweight or obesity but without diabetes. Foundational cardiovascular evidence for the Wegovy label expansion. N Engl J Med. 2023. PMID: 37952131.
- 7.Eli Lilly and Company. FOUNDAYO (orforglipron) tablets, for oral use — US Prescribing Information. FDA-approved April 1, 2026 to reduce excess body weight and maintain weight reduction in adults with obesity, or overweight with at least one weight-related comorbid condition. Dose escalation 0.8 / 2.5 / 5.5 mg, then optionally 9 / 14.5 / 17.2 mg once daily, at least 30 days per step. Section 14 Table 6: -11.1% (17.2 mg) vs -2.1% placebo at 72 weeks in adults without diabetes. Boxed warning for thyroid C-cell tumors. Sections 2.2 and 7: 9 mg maximum with strong CYP3A4 inhibitors; avoid strong CYP3A4 inhibitors that also inhibit OATP1B and strong CYP3A4 inducers. FDA Approved Labeling (DailyMed NIH). 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8ac446c5-feba-474f-a103-23facb9b5c62
- 8.Novo Nordisk Inc. WEGOVY (semaglutide) injection, for subcutaneous use; WEGOVY (semaglutide) tablets, for oral use — US Prescribing Information. Injection: weight reduction in adults and pediatric patients 12 and older, MACE risk reduction, and noncirrhotic MASH with F2–F3 fibrosis (accelerated approval); escalation 0.25 / 0.5 / 1 / 1.7 / 2.4 mg weekly, with an optional 7.2 mg maximum. Tablets: weight reduction and MACE risk reduction in adults; escalation 1.5 / 4 / 9 mg to 25 mg daily, taken fasting with up to 4 oz water. Section 14: -13.6% with 25 mg tablets at 64 weeks; -18.8% with 7.2 mg injection at 72 weeks. Boxed warning for thyroid C-cell tumors. FDA Approved Labeling (DailyMed NIH). 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b
- 9.Wharton S, Lingvay I, Bogdanski P, Duque do Vale R, Jacob S, Karlsson T, Shaji C, Rubino D, Garvey WT; OASIS 4 Study Group. Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity (OASIS 4). Once-daily oral semaglutide 25 mg vs placebo in 307 adults without diabetes; mean body-weight change at 64 weeks was -13.6% vs -2.2% (difference -11.4 percentage points). The trial behind the Wegovy tablet. N Engl J Med. 2025. PMID: 40934115.
- 10.Rosenstock J, Yabe D, Cox D, et al.; ACHIEVE-3 Investigators. Efficacy and safety of once-daily oral orforglipron compared with oral semaglutide in adults with type 2 diabetes (ACHIEVE-3): a multinational, multicentre, non-inferiority, open-label, randomised, phase 3 trial. Orforglipron 12 and 36 mg lowered HbA1c more than oral semaglutide 7 and 14 mg at 52 weeks, with more gastrointestinal events and adverse-event discontinuations. Lancet. 2026. PMID: 41765029.
- 11.Klein KR, Wysham C, Tuttle KR, Davies MJ, et al. Cardiovascular safety of orforglipron versus insulin glargine in adults with type 2 diabetes at increased cardiovascular risk (ACHIEVE-4): a phase 3, event-driven, randomised, open-label, non-inferiority, active comparator trial. MACE-4 occurred in 4.2% on orforglipron vs 5.0% on insulin glargine (HR 0.84, 95% CI 0.59-1.20), meeting non-inferiority. Lancet. 2026. PMID: 42815506.
- 12.Michalak W, Bøg M, Bendixen T, et al. Oral Semaglutide 25 mg Versus Orforglipron 36 mg in Obesity: A Population-Adjusted Indirect Treatment Comparison. Novo Nordisk-funded anchored comparison of OASIS 4 and ATTAIN-1 estimating 3.2 percentage points more weight loss with oral semaglutide 25 mg (95% CI -5.9 to -0.4). Diabetes Obes Metab. 2026. PMID: 42225305.
- 13.Cubanski J; KFF. CMS Extends Medicare's Short-Term Bridge Program for GLP-1 Obesity Drug Coverage. The Medicare GLP-1 Bridge, originally scheduled for July–December 2026, will run through the end of 2027. KFF. 2026. https://www.kff.org/quick-insights/cms-extends-medicares-short-term-bridge-program-for-glp-1-obesity-drug-coverage/
Key terms, explained
New to GLP-1s? Tap any term for a quick, plain-English definition.
- Foundayo · Drugs and brands
- Orforglipron · Drugs and brands
- Wegovy · Drugs and brands
- Semaglutide · Drugs and brands
- STEP-1 · Major trials
- Titration · Dosing
- MACE (Major Adverse Cardiovascular Events) · Major trials
Where to get GLP-1 safely: vetted online providers
Vetted telehealth providers that prescribe online. We compare pricing, form, and states served.
No insurance needed · vetted by our editors
WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. How we make money
From $139/mo
4-month plan rate
Ro
FDA-approved brand GLP-1s, including the Wegovy pill and Foundayo, with insurance help
Read full review →From $149/mo
+ required membership
Collective
The lowest flat medication price if you can absorb an annual membership fee
Read full review →From $59/mo
+ required membership